340B Drug Pricing Program
More than 20 years ago, Congress created the 340B Drug Pricing Program to allow eligible hospitals and health systems to stretch limited resources and expand access to care for vulnerable patients. But despite a proven track record of increasing patient access to vital medical services and…
This infographic PDF urges Congress to preserve the 340B program to protect access to care.
The Health Resources and Services Administration (HRSA) released today its long-awaited proposed 340B Drug Pricing Program "Mega Guidance" in the form of a notice with a 60-day comment period.
A July 6 Government Accountability Office (GAO) report examining Medicare Part B spending at hospitals participating in the 340B Drug Pricing Program draws unsubstantiated conclusions about a program that has a proven track record of improving access to care for poor patients and vulnerable…
The AHA today responded to a report that is the “latest in a series of attempts to misrepresent” the 340B Drug Pricing Program and the benefits it helps bring to poor patients and vulnerable communities.
A report paid for by a group backed by the pharmaceutical industry is the latest in a series of attempts to misrepresent a program that has a proven track record of helping poor patients and vulnerable communities.